Characteristics | All ILC | All IDC | Sp. Cor. | p | AUS-ILC | AUS-IDC | Sp. Cor. | p | HK-ILC | HK-IDC | Sp. Cor. | p | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Menopausal status (pre-, post-menopausal, MP) |  |  | −0.155 | <0.0005 |  |  | −0.160 | 0.003 |  |  | −0.135 | <0.0005 | |
 | No. (%) Post-MP | 89 (69.5%) | 601 (41.3%) |  |  | 36 (81.8%) | 174 (58.6%) |  |  | 53 (63.1%) | 427 (36.8%) |  |  |
Tumor size (≤2, >2-5, >5 cm) |  |  | −0.148 | <0.0005 |  |  | −0.145 | <0.0005 |  |  | −0.150 | <0.0005 | |
 | Median (cm) | 2.4 | 1.8 |  |  | 2.4 | 1.8 |  |  | 2.5 | 1.8 |  |  |
Tumor grade (1,2,3) | Â | Â | 0.205 | <0.0005 | Â | Â | 0.138 | <0.0005 | Â | Â | 0.239 | <0.0005 | |
 | No. (%) Grade 3 | 14 (6.5%) | 873 (49.5%) |  |  | 8 (8.5%) | 275 (44.3%) |  |  | 6 (4.9%) | 598 (52.3%) |  |  |
LN involvement (no, yes) |  |  | −0.007 | 0.761 |  |  | 0.007 | 0.852 |  |  | −0.011 | 0.706 | |
 | No. (%) Positive | 96 (42.7%) | 711 (41.6%) |  |  | 40 (47.1%) | 273 (48.1%) |  |  | 56 (40.0%) | 438 (38.4%) |  |  |
ER (negative, positive) |  |  | −0.121 | <0.0005 |  |  | −0.131 | 0.001 |  |  | −0.114 | <0.0005 | |
 | No. (%) Positive | 220 (94.8%) | 1416 (80.3%) |  |  | 91 (97.8%) | 512 (84.6%) |  |  | 129 (92.8%) | 904 (78.0%) |  |  |
PR (negative, positive) |  |  | −0.037 | 0.096 |  |  | −0.067 | 0.079 |  |  | −0.018 | 0.511 | |
 | No. (%) Positive | 182 (79.1%) | 1301 (74.0%) |  |  | 78 (84.8%) | 458 (76.6%) |  |  | 104 (75.4%) | 843 (72.7%) |  |  |
HER2 (negative, positive) | Â | Â | 0.095 | <0.0005 | Â | Â | 0.091 | 0.018 | Â | Â | 0.093 | 0.001 | |
 | No. (%) Negative | 210 (91.7%) | 1383 (80.3%) |  |  | 85 (93.4%) | 482 (84.0%) |  |  | 125 (90.6%) | 901 (78.5%) |  |  |
Ki67 (≤5, 6–9, ≥10) |  |  | 0.269 | <0.0005 |  |  | 0.191 | 0.002 |  |  | 0.252 | <0.0005 | |
 | Median | 5 | 15 |  |  | 5 | 15 |  |  | 6 | 15 |  |  |